Associations Between Free and Cued Selective Reminding Test and Cerebrospinal Fluid Biomarkers in Amnestic Mild Cognitive Impairment

J Alzheimers Dis. 2024;100(2):713-723. doi: 10.3233/JAD-240150.

Abstract

Background: The Free and Cued Selective Reminding Test (FCSRT), assessing verbal episodic memory with controlled learning and semantic cueing, has been recommended for detecting the genuine encoding and storage deficits characterizing AD-related memory disorders.

Objective: The present study aims at investigating the ability of FCSRT in predicting cerebrospinal fluid (CSF) evidence of amyloid-β positivity in subjects with amnestic mild cognitive impairment (aMCI) and exploring its associations with amyloidopathy, tauopathy and neurodegeneration biomarkers.

Methods: 120 aMCI subjects underwent comprehensive neurological and neuropsychological examinations, including the FCSRT assessment, and CSF collection; CSF Aβ42/40 ratio, p-tau181, and total-tau quantification were conducted by an automated CLEIA method on Lumipulse G1200. Based on the Aβ42/40 ratio value, subjects were classified as either A+ or A-.

Results: All FCSRT subitem scores were significantly lower in A+ group and significantly predicted the amyloid-β status, with Immediate Total Recall (ITR) being the best predictor. No significant correlations were found between FCSRT and CSF biomarkers in the A- aMCI group, while in the A+ aMCI group, all FCSRT subitem scores were negatively correlated with CSF p-tau181 and total-tau, but not with the Aβ42/40 ratio.

Conclusions: FCSRT confirms its validity as a tool for the diagnosis of AD, being able to predict the presence of amyloid-β deposition with high specificity. The associations between FCSRT subitem scores and CSF p-tau-181 and total-tau levels in aMCI due to AD could further encourage the clinical use of this simple and cost-effective test in the evaluation of individuals with aMCI.

Keywords: Alzheimer’s disease; amyloid-β; cerebrospinal fluid biomarkers; episodic memory; mild cognitive impairment; neurodegeneration.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Amnesia / cerebrospinal fluid
  • Amnesia / diagnosis
  • Amyloid beta-Peptides* / cerebrospinal fluid
  • Biomarkers* / cerebrospinal fluid
  • Cognitive Dysfunction* / cerebrospinal fluid
  • Cognitive Dysfunction* / diagnosis
  • Cues*
  • Female
  • Humans
  • Male
  • Memory, Episodic
  • Mental Recall / physiology
  • Middle Aged
  • Neuropsychological Tests*
  • Peptide Fragments* / cerebrospinal fluid
  • tau Proteins* / cerebrospinal fluid

Substances

  • Biomarkers
  • Amyloid beta-Peptides
  • tau Proteins
  • Peptide Fragments
  • amyloid beta-protein (1-42)